Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient

Fuda Cancer Hospital, Guangzhou

Status and phase: Completed; Phase 2; Phase 1

Conditions: Lung Neoplasms

Treatments: Other: standard treatment; Biological: MV mix vaccine

Study type: Interventional

Funder types: Other

Identifiers

NCT02333474

FudaCH

Details and patient eligibility

About

The purpose of this study is to evaluate the safeness and effectiveness of mix vaccine (MV). Enrolled patients will receive standard treatment according to National Comprehensive Cancer Network (NCCN) guide line with or without combining MV injection. The efficacy and side effect will be compared between the two groups.

Full description

In the study, after evaluation of the general and physical status, eligible patients will be enrolled and randomly assigned into two arms at an 1:1 ratio. In the control arm patients will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line (control group) and in experimental arm, patients will be receiving simultaneous standard therapy and injection of mix vaccine (MV). MV will be injected weekly till disease progression.

Blood sample will be obtained at baseline and every week before MV injection for the assessment of clinical hematology, biochemistry measurements and immunology index (including immunoglobin, interleukin and interferon). Patients will be evaluated for toxicity throughout the study. Side effect, progression free survival, immunology index and general status will be recorded.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients diagnosed with lung carcinoma based on histology
2. Evaluable lesions on imaging study
3. Without known immunodeficiency
4. Age >18 and <80 years ago

Exclusion criteria

1. Patients is unable or unwilling to sign informed consent
2. Any autoimmune disorder, which is currently being treated with prednisone or any other immune suppressive medication
3. Positive HIV and/or RPR (rapid plasma reagin )
4. Female patient who is pregnant or breast feeding
5. Patients, based on the opinion pf the investigator, should not be enrolled into this study
6. Prior anti-cancer vaccine or biological immunotherapy
7. Allergic to any known ingredient of the MV compound

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

20 participants in 2 patient groups

control

Active Comparator group

Description:

Patients in this group will be receiving standard therapy according to National Comprehensive Cancer Network (NCCN) guide line Version 2.2014.

Treatment:

Other: standard treatment

MV+control

Experimental group

Description:

Patients in this group will be receiving both standard therapy according to NCCN guide line Version 2.2014 and simultaneous injection of mix vaccine (MV). MV will be given

Treatment:

Biological: MV mix vaccine

Other: standard treatment